Form 4: Enanta Pharmaceuticals Chief Legal Officer Acquires 75,000 Stock Options

Enanta Pharmaceuticals' Chief Legal Officer, Matthew Paul Kowalsky, was granted 75,000 stock options on November 27, 2024.

Summary

• Matthew Paul Kowalsky, Chief Legal Officer of Enanta Pharmaceuticals, acquired 75,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• The options vest quarterly over four years from the grant date, meaning they become exercisable in stages.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options to the Chief Legal Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the pharmaceutical industry.
• The vesting schedule of four years is also typical, encouraging long-term commitment.
• Comparable companies in the biotech sector often use similar stock option plans to incentivize their executives.

Stakeholder Impact

• The stock option grant aligns the Chief Legal Officer's interests with those of shareholders, potentially leading to better company performance.
• The vesting schedule encourages long-term commitment from the executive.

Key Dates

Keywords

stock options, insider trading, executive compensation, Enanta Pharmaceuticals, ENTA, Matthew Paul Kowalsky, Chief Legal Officer